Replication, Fine-Mapping and Sequencing: Follow-Up on Genome-Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01)

The summary for the Replication, Fine-Mapping and Sequencing: Follow-Up on Genome-Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Replication, Fine-Mapping and Sequencing: Follow-Up on Genome-Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01)
	CFDA Number:	93.846
	CFDA Description:	Arthritis, Musculoskeletal and Skin Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PAR-09-135
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 20, 2009
	Creation Date:	Mar 20, 2009
	Original Closing Date for Applications:	Jun 29, 2011
	Current Closing Date for Applications:	Jun 29, 2011
	Archive Date:	Jul 30, 2011
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	$1,500,000
	Federal Grant Award Ceiling:	$250,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This Funding Opportunity Announcement (FOA), issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, encourages applications that propose to perform replication, fine-mapping, and sequencing studies of human genomic regions that are putatively associated with phenotypes relevant to the NIAMS mission. Genomic regions of interest are primarily those identified by genome-wide association studies (GWAS). The objective of this FOA is to enhance the identification of causal genes and genetic variants that influence complex diseases relevant to the NIAMS mission. Replication, fine-mapping, and sequencing studies are to be conducted in existing cohorts with defined phenotypes. This FOA will not support recruitment of human subjects, collection of medical or phenotypic data, studies using animal models, or the initial discovery phase of GWAS. Mechanism of Support. This FOA will utilize the NIH Research Project (R01) grant mechanism. In some instances, an active NIAMS R01 award may currently support a GWAS with a two-stage design, including initial discovery and replication. In such instances, investigators may submit a revision (formerly competing supplement) application in response to this FOA, to support additional replication, fine-mapping, or sequencing efforts, provided the application conforms to both the budgetary requirements of this FOA and the format requirements of revision applications. Funds Available and Anticipated Number of Awards. For this funding opportunity, the NIAMS expects to commit approximately $1.5 million total costs in each of fiscal years 2010, 2011, and 2012, to support three to four new projects per year. Budgets up to $250,000 direct costs per year and project periods of up to two years may be requested. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/par-09-135.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43); • NIAMS Clinical Trial Implementation Cooperative Agreement (U01); • Support of NIAMS Program Project Grants (P01); • Multidisciplinary Clinical Research Centers (P60); • NIAMS Multi-Center Clinical Study Implementation Planning Grants (U34); • COLLABORATIVE ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES SCIENCE AWARD (CAMSSA); • NIAMS SMALL GRANT PROGRAM FOR NEW INVESTIGATORS; • SKIN DISEASES RESEARCH CORE CENTERS; • CORE CENTERS FOR MUSULOSKELETAL DISORDERS; • MICROCIRCULATION AND TARGET ORGAN DAMAGE IN RHEUMATIC AND SKIN DISEASES